VIVUS Inc

VIVUS — Technical Presentation (June 2011)

5 slides from VIVUS's technical presentation, Jun 17, 2011

  1. Slide 1: Avanafil Post-Prostatectomy Erectile Dysfunction Study Poster: Introduction, Objectives, Methods

    Below is a reproduction of the contents of the poster entitled “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral, Nerve-Sparing Radical Prostatectomy”: John P. Mulhall

  2. Slide 2: Figure 1. Successful Vaginal Penetration (SEP 2; ITT)

    Figure 1. Successful Vaginal Penetration (SEP 2; ITT). Mean Percentage 38 $s Ha 32 SE 3 100 (n= *P001 va placebo Mi sacctne Ena of vearment

  3. Slide 3: Figure 2. Successful Intercourse Attempts (SEP 3; ITT)

    ‘igure 2. Successful Intercourse Attempts (SEP 3; ITT).

  4. Slide 4: Successful Intercourse by Postdose Time Interval

    Successful Intercourse by Postdose Time Interval · In total, 82.4% of sexual attempts studywide were made within 60 minutes or less. · One-third to one-half of all intercourse attempted at < 15 minutes and < 30 minutes was successful across both avanafil treatment groups (Figure 4).

  5. Slide 5: Safety Summary

    Safety Summary · Discontinuations or interruptions of study drug due to adverse events (AEs) were 3%, 3%, and 2% for placebo, 100 mg, and 200 mg, respectively (Table 2). · There were no serious AEs and no deaths during the study Table 2. Summary of Adverse Events (Safety Population). Subjects With A

Vivus — Technical Presentation (June 2011) on 6ix